ストックスクリーナーアプリを入手
4.91
0.41%
0.02
アフターアワーズ：
4.90
-0.010
-0.20%
前日終値:
$4.89
開ける：
$5.06
24時間の取引高:
133.71K
Relative Volume:
2.37
時価総額：
$140.84M
収益：
$4.40M
当期純損益:
$-60.78M
株価収益率:
-1.7347
EPS:
-2.8305
ネットキャッシュフロー:
$-23.91M
1週間 パフォーマンス:
-9.91%
1か月 パフォーマンス:
-11.85%
6か月 パフォーマンス:
+59.42%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$4.601
$5.39
1週間の範囲:
$4.601
$5.59
52週間の値動き範囲:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
名前
Insight Molecular Diagnostics Inc
セクター
電話
949-409-7600
住所
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
4.91 | 140.84M | 4.40M | -60.78M | -23.91M | -2.8305 |
|
TMO
Thermo Fisher Scientific Inc
|
464.37 | 172.51B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
187.32 | 132.46B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
573.82 | 45.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.51 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
286.57 | 28.11B | 3.17B | 642.63M | 516.49M | 10.77 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-28 | 開始されました | Lake Street | Buy |
| 2022-05-24 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-03-17 | 再開されました | Needham | Buy |
| 2021-01-07 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 開始されました | BTIG Research | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 繰り返されました | The Benchmark Company | Speculative Buy |
| 2020-07-01 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 開始されました | Needham | Buy |
| 2019-02-13 | 開始されました | Piper Jaffray | Overweight |
| 2019-01-29 | アップグレード | Janney | Neutral → Buy |
| 2018-12-19 | 再開されました | Lake Street | Buy |
すべてを表示
Insight Molecular Diagnostics Inc (IMDX) 最新ニュース
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Capital And GraftAssureDx Milestones - Yahoo Finance
Certain Warrants of Insight Molecular Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2026. - marketscreener.com
Insight Molecular Diagnostics (IMDX) Advances with GraftAssure T - GuruFocus
Insight Molecular Diagnostics Inc Highlights New Peer-Reviewed Study Demonstrating GraftAssure Assay Technology Superiority - marketscreener.com
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score - GlobeNewswire
Insight Molecular Diagnostics Nears FDA Submission for Kidney Transplant Rejection Test Kit - Clinical Lab Products
Insight Molecular Diagnostics Nears FDA Submission with GraftAssureDx Milestones - Zenopa
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission - Bitget
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Insight Molecular Diagnostics completes key milestones advancing Graftassuredx toward FDA submission - marketscreener.com
Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission - TradingView
Kidney transplant test GraftAssureDx nears FDA submission in $2B market - Stock Titan
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And GraftAssureDx Catalyst - Yahoo Finance
Insight Molecular Diagnostics enters agreement with Quest DiagnosticsSEC filing - marketscreener.com
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement - TipRanks
In Insight Molecular Diagnostics Inc. Enters into A Specimen Collection Agreement with Quest Diagnostics Incorporated - marketscreener.com
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Insight Molecular Diagnostics Inc. has reached a service agreement with Quest Diagnostics. - Bitget
Insight Molecular Diagnostics (IMDX) Price Target Increased by 19.05% to 8.50 - Nasdaq
Kidney Transplant Rejection Market Overview: Major Segments, Strategic Developments, and Leading Companies - openPR.com
IMDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Molecular Biology Analyzers Market Set to Boom by 2033: - openPR.com
Insight Molecular (IMDX) Sees Analyst Price Target Raised to $12 - GuruFocus
Of Note: Nashville Zoo adds to board - Nashville Post
Insider Stock Purchases: February 13, 2026 - Quiver Quantitative
Insight Molecular Diagnostics Raises Capital to Advance Transplant R&D - TipRanks
Insight Molecular Diagnostics Signs Multiple Material Agreements - TradingView
From $54B to $85B: A Promising Decade for North America IVD - GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Imdx announces $26.0 million registered direct offering - marketscreener.com
Insight Molecular Diagnostics (IMDX) Secures $26M in Direct Stoc - GuruFocus
Insight Molecular Diagnostics prices $26M registered direct offering; shares down - MSN
Insight Molecular Diagnostics Provides Updated Investor Presentation Materials - TipRanks
iMDx Announces $26.0 Million Registered Direct Offering - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Boston Scientific (BSX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Steris (STE) and Roche Holding AG (OtherRHHVF) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Artivion (AORT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), NewAmsterdam Pharma Company (NAMS) and Resmed (RMD) - The Globe and Mail
Gastric Cancer Diagnostic Procedure Market to Grow at a CAGR of 6.53% - industrytoday.co.uk
Urinary Tract Infection Testing Market | Global Market Analysis Report2036 - Future Market Insights
Bullish Insight Molecular Diagnostics Insiders Rewarded As Their Investment Rises To US$8.13m - simplywall.st
Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Dexcom (DXCM) - The Globe and Mail
IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring - marketscreener.com
Insight ‘congratulated’ STAR working group on organ health testing paper - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring - marketscreener.com
Transplant leaders urge decentralized organ rejection tests at hospitals - Stock Titan
iMDx Announces 'JPM Week” and 'BTIG Snowbird” Conference Participation - The Manila Times
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation - GlobeNewswire
iMDx to Welcome Industry Veteran as Vice President of - GlobeNewswire
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch - Sahm
Is Insight Molecular Diagnostics Inc. (7OC0) stock considered safe haven2026 world cup usa national team quarterfinals midfield engines low block defense group prediction preview - Улправда
Insight Molecular Diagnostics Inc (IMDX) 財務データ
収益
当期純利益
現金流量
EPS
0.34%
0.59%
大文字化:
|
ボリューム (24 時間):